Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCARFREE-001: Verteporfin for Scar Prevention
2025-525083-14-00Phase 2Authorised
- Sponsor
- University Hospital Odense
- Start
- May 2026
- Modality
- Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of verteporfin in Post-surgical scarring (4 arms), sponsored by University Hospital Odense. Primary endpoints: Closed wound scar quality (Observer POSAS at 3 months) and Open wound scar quality (Observer POSAS at 3 months). Planned start May 2026; status: authorised.
02
Drugs
verteporfin
03
Conditions
Post-surgical scarring
Beyond the preview
Go deeper on 2025-525083-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-525083-14-00.